4.30
price down icon1.60%   -0.07
pre-market  Pre-market:  4.05   -0.25   -5.81%
loading
Cogent Biosciences Inc stock is traded at $4.30, with a volume of 957.07K. It is down -1.60% in the last 24 hours and down -39.94% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$4.37
Open:
$4.29
24h Volume:
957.07K
Relative Volume:
0.68
Market Cap:
$521.43M
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-1.7339
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
-6.11%
1M Performance:
-39.94%
6M Performance:
-63.74%
1Y Performance:
-35.92%
1-Day Range:
Value
$4.20
$4.43
1-Week Range:
Value
$4.115
$5.09
52-Week Range:
Value
$3.72
$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name
Name
Cogent Biosciences Inc
Name
Phone
617-945-5576
Name
Address
275 WYMAN STREET, WALTHAM
Name
Employee
205
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
COGT's Discussions on Twitter

Compare COGT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
COGT
Cogent Biosciences Inc
4.30 521.43M 0 -242.30M -192.10M -2.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-11-24 Downgrade Needham Buy → Hold
Feb-26-24 Downgrade Robert W. Baird Outperform → Neutral
Feb-08-24 Initiated Citigroup Buy
Dec-11-23 Downgrade Wedbush Outperform → Neutral
Dec-08-23 Initiated JP Morgan Overweight
Apr-28-23 Initiated Robert W. Baird Outperform
Mar-27-23 Resumed H.C. Wainwright Buy
Dec-14-22 Initiated Needham Buy
Jun-28-22 Initiated Guggenheim Buy
Oct-11-21 Initiated H.C. Wainwright Buy
Jun-09-21 Resumed Jefferies Buy
Dec-23-20 Initiated Piper Sandler Overweight
Oct-14-20 Initiated Ladenburg Thalmann Buy
View All

Cogent Biosciences Inc Stock (COGT) Latest News

pulisher
Apr 21, 2025

Cogent Biosciences Inc (COGT) Becoming More Attractive for Investors - knoxdaily.com

Apr 21, 2025
pulisher
Apr 20, 2025

(COGT) Technical Data - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 20, 2025

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts - Insider Monkey

Apr 20, 2025
pulisher
Apr 20, 2025

Geode Capital Management LLC Boosts Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Apr 20, 2025
pulisher
Apr 16, 2025

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 16, 2025
pulisher
Apr 15, 2025

Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Apr 15, 2025
pulisher
Apr 13, 2025

Vanguard Group Inc. Purchases 418,975 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Trims Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

KLP Kapitalforvaltning AS Takes $88,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement - Seeking Alpha

Apr 09, 2025
pulisher
Apr 08, 2025

Cogent Biosciences stock hits 52-week low at $4.24 By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Cogent Biosciences stock hits 52-week low at $4.24 - Investing.com

Apr 08, 2025
pulisher
Apr 04, 2025

Trend Tracker for (COGT) - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.43 Consensus PT from Brokerages - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com

Mar 31, 2025
pulisher
Mar 31, 2025

21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo

Mar 29, 2025
pulisher
Mar 29, 2025

Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire

Mar 26, 2025
pulisher
Mar 25, 2025

Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan

Mar 25, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - TradingView

Mar 20, 2025
pulisher
Mar 18, 2025

Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Insider Monkey

Mar 17, 2025
pulisher
Mar 14, 2025

Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter

Mar 10, 2025
pulisher
Mar 09, 2025

Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 08, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

When the Price of (COGT) Talks, People Listen - Stock Traders Daily

Mar 03, 2025
pulisher
Feb 28, 2025

Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Equities Analysts Lift Earnings Estimates for COGT - The AM Reporter

Feb 28, 2025
pulisher
Feb 28, 2025

Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 27, 2025

Cogent Biosciences Inc Stock (COGT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):